...
首页> 外文期刊>Seminars in Respiratory and Critical Care Medicine >Assessing severity of patients with community-acquired pneumonia
【24h】

Assessing severity of patients with community-acquired pneumonia

机译:评估社区获得性肺炎患者的严重程度

获取原文
获取原文并翻译 | 示例
           

摘要

Despite all advances in its management, community-acquired pneumonia (CAP) is still an important cause of morbidity and mortality requiring a great consumption of health, social, and economic resources. An early and adequate severity assessment is of paramount importance to provide optimized care to these patients. In the last 2 decades, this issue has been the subject of extensive research. Based on 30 day mortality, several prediction rules have been proposed to aid clinicians in deciding on the appropriate site of care. In spite of being well validated, their sensitivity and specificity vary, which limits their widespread use. The utility of biomarkers to overcome this problem has been investigated. At this moment, their full clinical value remains undetermined, and no single biomarker is consistently ideal for assessing CAP severity. Biomarkers should be seen as a complement rather than superseding clinical judgment or validated clinical scores. The search for a gold standard is not over, and new tools, like bacterial DNA load, are in the pipeline. Until then, CAP severity assessment should be based in three key points: a pneumonia-specific score, biomarkers, and clinical judgment.
机译:尽管其管理取得了所有进展,但社区获得性肺炎(CAP)仍然是致病和致死的重要原因,需要大量消耗健康,社会和经济资源。尽早进行充分的严重程度评估对于为这些患者提供最佳护理至关重要。在过去的20年中,这个问题一直是广泛研究的主题。根据30天的死亡率,提出了一些预测规则,以帮助临床医生确定合适的护理地点。尽管得到了很好的验证,但它们的敏感性和特异性却各不相同,这限制了它们的广泛使用。已经研究了生物标志物用于克服该问题的效用。目前,它们的全部临床价值尚未确定,并且没有单一的生物标志物始终是评估CAP严重性的理想选择。生物标志物应被视为补充,而不是取代临床判断或经过验证的临床评分。寻找黄金标准的工作尚未结束,并且新工具(如细菌DNA负载)正在酝酿中。在此之前,CAP严重程度评估应基于三个关键点:肺炎特异性评分,生物标志物和临床判断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号